Parathyroid Hormone Market Report 2025

This Parathyroid Hormone market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The parathyroid hormone market size has grown steadily in recent years. It will grow from $2.35 billion in 2024 to $2.43 billion in 2025 at a compound annual growth rate (CAGR) of 3.5%. The growth in the historic period can be attributed to rising prevalence of chronic kidney disease, increasing awareness of parathyroid hormone-related disorders, growing demand for parathyroid hormone analogs, increased government funding for parathyroid hormone research, rising disposable incomes.

The parathyroid hormone market size is expected to see strong growth in the next few years. It will grow to $3.5 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to growing geriatric population, expansion of private healthcare sectors, emerging indications, precision medicine, growing awareness of bone health, expanding healthcare access. Major trends in the forecast period include advances in parathyroid hormone testing, advances in drug delivery, combination therapies, digital health integration, sustainability and green initiatives.

The market for parathyroid hormones anticipates growth due to rising osteoporosis prevalence. In January 2021, Osteoporosis, characterized by reduced bone mass leading to higher fracture risks, affects approximately 1.4 million Canadians, primarily postmenopausal women and the elderly. Parathyroid hormones, regulating calcium levels, are administered via daily subcutaneous injections to mitigate fracture risks in osteoporosis patients. This surge in osteoporosis cases is expected to contribute to the expansion of the parathyroid hormone market.

The growing geriatric population is expected to drive the growth of the parathyroid hormone market in the future. The geriatric population refers to older adults, typically aged 65 and older, who may face age-related health challenges and require specialized care and support. This demographic shift is largely due to increased life expectancy, advancements in healthcare, and declining birth rates, leading to a larger proportion of elderly individuals in society. Parathyroid hormone plays a crucial role for this demographic as it regulates calcium levels and bone metabolism, helping to prevent conditions such as osteoporosis and fractures, which are prevalent among older adults. For example, in January 2024, the Population Reference Bureau, a US-based nonprofit organization, projected that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Additionally, this age group’s share of the total population is expected to grow from 17% to 23% during the same period. Therefore, the increasing geriatric population is driving the expansion of the parathyroid hormone market.

Major companies in the parathyroid hormone market are increasingly focused on developing biosimilars of parathyroid-based drugs, such as prodrugs of parathyroid hormone (PTH), to expand treatment options. A prodrug of parathyroid hormone is an inactive compound that converts into active PTH after administration, allowing for prolonged release and stable therapeutic outcomes in calcium regulation and bone health. For example, in August 2024, Ascendis Pharma A/S, a biopharmaceutical company based in Denmark, announced that the Food and Drug Administration (FDA) approved YORVIPATH (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adults. This once-daily prodrug ensures continuous exposure to PTH, benefiting an estimated 70,000 to 90,000 patients in the United States. Ascendis Pharma supports patients through its Ascendis Signature Access Program (A.S.A.P.), although users must regularly monitor their serum calcium levels to detect potential hypercalcemia or hypocalcemia.

Major companies in the parathyroid hormone market are concentrating on innovative solutions, such as prodrugs, to enhance drug performance. A prodrug is an inactive compound that is metabolically converted into an active drug within the body. For example, in August 2022, Ascendis Pharma A/S, a biopharmaceutical company based in Denmark, submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational therapy, TransCon PTH (palopegteriparatide), intended for treating adult patients with hypoparathyroidism. TransCon PTH is a long-acting prodrug of parathyroid hormone designed to restore physiological PTH levels over a 24-hour period. This is essential for managing hypoparathyroidism, a condition characterized by insufficient parathyroid hormone production, which results in low calcium levels and related health complications.

Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, announced its decision to acquire Shire Plc for $46 billion. The acquisition is expected to accelerate the delivery of medicines to patients around the world with an expanded scale and geographical footprint by Takeda Pharmaceutical Company. It also increases the levels of the parathyroid hormone, natpara. Shire Plc is a pharmaceutical company based in the United States that specializes in innovative and rare disease drugs.

Parathyroid hormone, produced by the parathyroid gland, plays a crucial role in the body's calcium storage and utilization. Elevated levels of this hormone can lead to high blood calcium levels, potentially indicating a medical condition. It's also referred to as PTH, parathyrin, or parathormone.

Within the realm of parathyroid hormone products, there are recombinant parathyroid hormone and parathyroid hormone analogs. Recombinant parathyroid hormone, resembling natural parathyroid hormone, is utilized in treating osteoporosis. These products cater to conditions like hypocalcemia and hypoparathyroidism and are used across various healthcare settings such as hospitals, clinics, and others.

The parathyroid hormone market research report is one of a series of new reports that provides parathyroid hormone market statistics, including parathyroid hormone industry global market size, regional shares, competitors with a parathyroid hormone market share, detailed parathyroid hormone market segments, market trends and opportunities, and any further data you may need to thrive in the parathyroid hormone industry. This parathyroid hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the parathyroid hormone market include Pfizer Inc., Eli Lilly and Company, Radius Health Inc., Ascendis Pharma, Entera Bio Ltd., Extend Biosciences Inc., Gedeon Richter Plc., Abbott Laboratories, Amgen Inc., Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Bayer Healthcare, AstraZeneca PLC, Biocon, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Jubilant Life Sciences, Lupin Limited, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Wockhardt, Cipla Limited.

North America was the largest region in the parathyroid hormone market in 2024. The Middle East is expected to be the fastest-growing region in the global parathyroid hormone market share during the forecast period. The regions covered in the parathyroid hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the parathyroid hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The parathyroid hormone market consists of sales of parathormone and calcitonin. Values in this market are ''factory gate values,'' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.